Unique design, size, and material expected to improve safety and care
IRVINE, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI),
the inventor of Pulse CO-Oximetry and Measure-Through Motion and Low Perfusion
pulse oximetry, announced a new SofTouch(TM) disposable pulse oximetry sensor
developed specifically for the fragile skin and size of extremely low birth
weight (ELBW) infants (<500 grams-1,000 grams) in conjunction with the
Neonatology 2008 conference in Miami, Florida. The new LNCS(R) SofTouch
NeoPt-500 sensor is exclusively designed to fit ELBW babies and features
special soft foam and non-adhesive attachments to prevent injury to even the
most sensitive skin of premature infants.
Barbara Haley, CRTT, NICU Clinical Coordinator, Respiratory Care Services
at California Pacific Medical Center in San Francisco, CA, stated; "We love
the LNCS SofTouch NeoPt-500 for the improvement in care it facilitates. It is
smaller than other neonatal sensors -- making it a near-perfect fit even for
our smallest preemies -- and it is much softer on the skin to maintain skin
integrity. We've also found that the NeoPt-500 makes nurses more efficient
because the wrap is so much easier to apply and secure."
LNCS SofTouch NeoPt-500 is the first non-adhesive pulse oximetry sensor
made specifically for the needs of newborns weighing down to 500 grams or
less. At just 20 mm in size, the NeoPt-500 has dimensions that are smaller
than typical neonatal sensors. This means that the distance between the
emitter and detector on the NeoPt-500 is much smaller -- enabling the sensor
to fit better and more securely on the tiniest hand or foot.
Mitchell Goldstein, M.D., Associate Professor, Pediatrics at Loma Linda
University Children's Hospital in Loma Linda, CA, stated; "The new LNCS(R)
SofTouch NeoPt-500 sensor solves the problems associated with typical pulse
oximetry sensors in ELBW infants. ELBW neonates are much more susceptible to
skin burn injury and full thickness ulcer formations caused by improper sensor
design and placement. Skin injury compromises the body's most basic protection
mechanism and, in this most vulnerable population, the problems and risks
associated with sensors not designed or intended for ELBW newborns have much
greater consequences. Masimo is a unique company that not only understands
this, but designs and develops clinically-relevant solutions to overcome these
challenges."
Masimo SofTouch sensors are designed for single-patient use whenever skin
sensitivity is a concern. SofTouch sensors incorporate a hook and loop wrap
-- allowing the sensor to be quickly and securely applied on wet and slippery
sites, and easily repositioned if necessary. Newborn skin is further
protected by soft foam material that surrounds the sensor attachment for
maximum comfort, and the NeoPt-500 contains no adhesive materials exposed to
skin contact areas. This prevents epidermal stripping and skin trauma
typically caused by applying and repositioning an adhesive sensor.
Joe E. Kiani, Founder and CEO of Masimo, stated; "The new LNCS SofTouch
NeoPt-500 sensor underscores our core philosophy of 'doing what is best for
patient care.' We believe that every patient deserves appropriate monitoring
solutions. That's why Masimo provides over 100 different sensors, each
uniquely designed to deliver the performance and measurement clinicians want
-- including 15 different sensor options to address the challenging needs and
specific requirements of neonatal patients."
About Masimo
Masimo (NASDAQ: MASI) develops innovative monitoring technologies that
significantly improve patient care -- helping solve "unsolvable" problems. In
1995, the company debuted Measure-Through-Motion-and-Low-Perfusion pulse
oximetry, known as Masimo SET, which virtually eliminated false alarms and
increased pulse oximetry's ability to detect life-threatening events. More
than 100 independent and objective studies demonstrate Masimo SET provides the
most reliable SpO2 and pulse rate measurements even under the most challenging
clinical conditions, including patient motion and low peripheral perfusion.
In 2005, Masimo introduced Masimo Rainbow SET Pulse CO-Oximetry, a
breakthrough noninvasive blood constituent monitoring platform that can
measure many blood constituents that previously required invasive procedures.
Masimo Rainbow SET continuously and noninvasively measures total hemoglobin
(SpHb(TM)), oxygen content (SpOC(TM)), carboxyhemoglobin (SpCO(R)),
methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2),
pulse rate (PR), and perfusion index (PI), allowing early detection and
treatment of potentially life-threatening conditions. Founded in 1989, Masimo
has the mission of "Improving Patient Outcomes and Reducing Cost of Care by
Taking Noninvasive Monitoring to New Sites and Applications." Additional
information about Masimo and its products may be found at
http://www.masimo.com.
Forward Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, in connection with the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are based on current
expectations about future events affecting us and are subject to risks and
uncertainties, all of which are difficult to predict and many of which are
beyond our control and could cause our actual results to differ materially and
adversely from those expressed in our forward-looking statements as a result
of various risk factors, including, but not limited to: risks related to our
assumption that the addition of the LNCS(R) NeoPt-500 SofTouch(TM)(R) sensor
will outperform other neonatal pulse oximetry sensors and will serve to
increase clinical accuracy and efficiency and the adoption of Masimo
technology, or serve to substantially increase sensor sales, as well as other
factors discussed in the "Risk Factors" section of our Quarterly Report on
Form 10-Q for the fiscal quarter ended September 27, 2008, filed with the
Securities and Exchange Commission ("SEC") on October 29, 2008, which may be
obtained for free at the SEC's website at http://www.sec.gov. Although we
believe that the expectations reflected in our forward-looking statements are
reasonable, we do not know whether our expectations will prove correct. All
forward-looking statements included in this press release are expressly
qualified in their entirety by the foregoing cautionary statements. You are
cautioned not to place undue reliance on these forward-looking statements,
which speak only as of today's date. We do not undertake any obligation to
update, amend or clarify these forward-looking statements or the "Risk
Factors" contained in our Quarterly Report on Form 10-Q for the fiscal quarter
ended September 27, 2008, whether as a result of new information, future
events or otherwise, except as may be required under the applicable securities
laws.
Contact: Dana Banks
Masimo Corporation
949-297-7348
Masimo, SET, Signal Extraction Technology, Improving Outcomes and Reducing
Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications,
Rainbow, SpHb, SpOC, SpCO, SpMet, PVI, Radical-7, Rad-87, Rad-57,Rad-9, Rad-8,
Rad-5,Pulse CO-Oximetry and Pulse CO-Oximeter are trademarks or registered
trademarks of Masimo Corporation.
SOURCE Masimo
-0- 11/05/2008
/CONTACT: Dana Banks of Masimo Corporation, +1-949-297-7348/
/Web site: http://www.masimo.com /
(MASI)
CO: Masimo
ST: California
IN: HEA MTC
SU: PDT
JR-JC
-- LAW532 --
6649 11/05/2008 15:16 EST http://www.prnewswire.com